Invent: Health

Speed is not normally something you would associate with the highly regulated world of health tech. “Rapid” time frames tend to be in the space of 3-5 years. But the Covid panic changed this - the war footing it caused brought times down enormously. It’s something that TTP played a hand in as well with Covent, TTP’s rapid manufacture ventilator for COVID-19 patients. So what can we learn from this period to bring to normal times? How can health tech practitioners work with regulators and the NHS to ensure new innovations move from idea to impact as quickly as possible? How can we achieve truly rapid innovation?

Dr. Edwin Stone is a consultant at TTP who now leads Cellular Origins, a TTP spin-out created to enable scalable and cost-effective manufacture of cell and gene therapies. Before this, he worked on some of the earliest EMA-approved cell therapies and has been involved in the development of over 10 novel cell therapy automation platforms. He was also closely involved in Covent, TTP’s rapid manufacture ventilator for COVID-19 patients. Connect with Edwin on LinkedIn.

With over 25 years' experience in the pharmaceutical and HealthTech industries, Luella’s career has seen her hold numerous specialist manufacturing and commercial roles, with responsibility for a range of product portfolios across the HealthTech spectrum within the UK, Europe, Middle East and Africa. In 2019 she joined the ABHI as their director of value and access, an organisation who represent and support the entire industry to stakeholders, including the government, NHS, and regulators. Connect with Luella on LinkedIn.